Imunon presents data from its Phase 2 OVATION 2 study of IMNN-001

IMUNON (IMNN) announced the presentation of new positive translational data from the Phase 2 OVATION 2 Study of IMNN-001, its investigational gene-based interleukin-12, IL-12, immunotherapy based on the Company’s proprietary TheraPlas technology platform, for the treatment of newly diagnosed advanced ovarian cancer. Results are being highlighted in a poster presentation at the ESMO Gynaecological Cancers Congress 2025, taking place June 19-21, 2025, in Vienna, Austria. The Phase 2 OVATION 2 Study assessed 112 participants treated with IMNN-001 plus standard-of-care neoadjuvant and adjuvant chemotherapy. IL-12 levels were sampled in the peritoneal fluid cavity, which is the primary tumor micro-environment. Results being presented at the ESMO Congress showed that treatment with IMNN-001 induced substantial increases in IL-12 and interferon-gamma and tumor necrosis factor-alpha, key downstream anti-cancer immune cytokines. Increases in IL-12, IFN-gamma and TNF-alpha levels in the peritoneal cavity were approximately 27-, 62- and 36-fold following treatment, respectively, demonstrating the tumor-localized effect of IMNN-001 in women with advanced ovarian cancer. IMNN-001 continues to show a favorable safety profile.